[
    [
        {
            "time": "",
            "original_text": "速读社丨艾尔健裁员1000人 强生长效抗精神药物获FDA批准标签更新",
            "features": {
                "keywords": [
                    "艾尔健",
                    "裁员",
                    "强生",
                    "抗精神病药物",
                    "FDA批准"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "速读社丨艾尔健裁员1000人 强生长效抗精神药物获FDA批准标签更新",
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "【行业深度】医药生物李平祝/霍辰伊拥抱医药创新的新时代—创新药产业深度报告暨2018年投资策略",
            "features": {
                "keywords": [
                    "医药创新",
                    "投资策略",
                    "创新药产业"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【行业深度】医药生物李平祝/霍辰伊拥抱医药创新的新时代—创新药产业深度报告暨2018年投资策略",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 6,
                "Duration": 9,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 4
            }
        },
        {
            "time": "",
            "original_text": "出让资产经营不达标 沃森生物将承担相应赔付责任",
            "features": {
                "keywords": [
                    "沃森生物",
                    "资产出让",
                    "赔付责任"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "出让资产经营不达标 沃森生物将承担相应赔付责任",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        }
    ]
]